Pharmaceutical

CBIH Charts Path to Future Leadership in Cannabis Medicine

A letter from our desk HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Since the start of the year, Cannabis Bioscience…

6 months ago

ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan

For the treatment of Borderline Personality Disorder (BPD) and Attention Deficit Hyperactivity disorder (ADHD)MADRID and CAMBRIDGE, Mass., July 08, 2024…

6 months ago

Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia

Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia Approximately 10 million adults in…

6 months ago

Belite Bio to Present at the JonesHealthcare Seaside Summit

SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused…

6 months ago

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

6 months ago

Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024

SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today…

6 months ago

Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher

UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the UK…

6 months ago

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish…

6 months ago

HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants

The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development…

6 months ago